<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic treatment for unresectable pleural mesothelioma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic treatment for unresectable pleural mesothelioma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Systemic treatment for unresectable pleural mesothelioma</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Treatment approaches for patients with pleural mesothelioma are evolving, and patients are encouraged to participate in clinical trials, when possible.</div><div class="graphic_footnotes">* Contributors are divided in regards to whether or not they offer maintenance therapy after pemetrexed plus platinum. While some offer pemetrexed or bevacizumab maintenance to those without contraindications, others do not offer maintenance therapy. In the setting of limited data suggesting modest benefit, a choice regarding maintenance therapy should be made based on individual patient comorbidities and preferences.<br/>¶ Immunotherapy with nivolumab plus ipilimumab is an appropriate alternative in this setting, particularly for those who are not candidates for the doublet of pemetrexed plus platinum.<br/>Δ Immunotherapy options include the combination of nivolumab plus ipilimumab, or for those who are less likely to tolerate this combination, single-agent pembrolizumab or nivolumab. Single-agent chemotherapy options include gemcitabine, vinca alkaloids, or anthracyclines.</div><div id="graphicVersion">Graphic 130516 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
